Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 7, 2011, Pages 1257-1266

  Schroeder, Rogier P J ^a   Van Weerden, W M ^a   Krenning, E P ^a   Bangma, C H ^a   Berndsen, S ^a   Grievink De Ligt, C H ^a   Groen, H C ^a   Reneman, S ^a   De Blois, E ^a   Breeman, W A P ^a   De Jong, M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bombesin; Choline; Metabolism based tracer; Positron emission tomography; Prostatic neoplasms; Xenograft model

Indexed keywords

4 AMINOMETHYLBENZOIC ACID; BOMBESIN DERIVATIVE; CHOLINE; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GASTRIN RELEASING PEPTIDE RECEPTOR; TRACER;

ARTICLE; IN VIVO STUDY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SCINTIGRAPHY;

ANIMALS; BOMBESIN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHOLINE; FLUORINE RADIOISOTOPES; GALLIUM RADIOISOTOPES; HUMANS; MALE; MICE; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RECEPTORS, BOMBESIN;

EID: 79958060431     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1775-3     Document Type: Article

References (39)

1. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics, 2009 CA Cancer J Clin 59 4 225 249 19474385 10.3322/caac.20006
2. OW Brawley 2009 Prostate cancer screening; is this a teachable moment? J Natl Cancer Inst 101 19 1295 1297 19720970 10.1093/jnci/djp310
3. HG Welch PC Albertsen 2009 Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005 J Natl Cancer Inst 101 19 1325 1329 19720969 10.1093/jnci/djp278
4. P Castellucci C Fuccio C Nanni I Santi A Rizzello F Lodi, et al. 2009 Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy J Nucl Med 50 9 1394 1400 19690023 10.2967/jnumed.108.061507
5. S Jana MD Blaufox 2006 Nuclear medicine studies of the prostate, testes, and bladder Semin Nucl Med 36 1 51 72 16356796 10.1053/j.semnuclmed.2005.09.001 (Pubitemid 41779367)
6. KK Yu H Hricak 2000 Imaging prostate cancer Radiol Clin North Am 38 1 59 85 10664667 10.1016/S0033-8389(05)70150-0 viii (Pubitemid 30059006)
7. R Markwalder JC Reubi 1999 Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation Cancer Res 59 5 1152 1159 10070977 1:CAS:528:DyaK1MXhslertrc%3D (Pubitemid 29135980)
8. RP Schroeder WM van Weerden C Bangma EP Krenning M de Jong 2009 Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues Methods 48 2 200 204 19398012 10.1016/j.ymeth.2009.04.002 1:CAS:528: DC%2BD1MXmvFymtb0%3D
9. LE Lantry E Cappelletti ME Maddalena JS Fox W Feng J Chen, et al. 2006 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer J Nucl Med 47 7 1144 1152 16818949 1:CAS:528:DC%2BD28XnslSmtrc%3D (Pubitemid 47558898)
10. RP Schroeder C Muller S Reneman ML Melis WA Breeman E de Blois, et al. 2010 A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues Eur J Nucl Med Mol Imaging 37 7 1386 1396 10.1007/s00259-010-1388-2 20182713 10.1007/s00259-010-1388-2 1:CAS:528:DC%2BC3cXns1Sis7k%3D
11. PL Jager MA de Korte MN Lub-de Hooge A van Waarde KP Koopmans PJ Perik, et al. 2005 Molecular imaging: what can be used today Cancer Imaging 5 Spec No A S27 S32 16361133 10.1102/1470-7330.2005.0023
12. GJ Cook 2003 Oncological molecular imaging: nuclear medicine techniques Br J Radiol 76 Spec No 2 S152 S158 15572337 10.1259/bjr/16098061 1:CAS:528:DC%2BD2cXhtFChur3F (Pubitemid 39530308)
13. PJ Effert R Bares S Handt JM Wolff U Bull G Jakse 1996 Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose J Urol 155 3 994 998 8583625 10.1016/S0022-5347(01)66366-3 1:STN:280:DyaK287msVKnug%3D%3D (Pubitemid 26052696)
14. C Hofer C Laubenbacher T Block J Breul R Hartung M Schwaiger 1999 Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy Eur Urol 36 1 31 35 10364652 10.1159/000019923 1:STN:280:DyaK1M3psVOiuw%3D%3D (Pubitemid 29265277)
15. IJ de Jong J Pruim PH Elsinga W Vaalburg HJ Mensink 2003 Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET J Nucl Med 44 3 331 335 12620996 (Pubitemid 39586006)
16. J Kotzerke BG Volkmer G Glatting J van den Hoff JE Gschwend P Messer, et al. 2003 Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer Nuklearmedizin 42 1 25 30 12601451 1:CAS:528:DC%2BD3sXjslegtL4%3D (Pubitemid 36231688)
17. J Kotzerke BG Volkmer B Neumaier JE Gschwend RE Hautmann SN Reske 2002 Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer Eur J Nucl Med Mol Imaging 29 10 1380 1384 12271422 10.1007/s00259-002-0882-6 1:CAS:528:DC%2BD38Xnt1Gnsrc%3D (Pubitemid 44392221)
18. C Nanni P Castellucci M Farsad D Rubello S Fanti 2007 11C/18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended? Eur J Nucl Med Mol Imaging 34 10 1704 1705 17619877 10.1007/s00259-007-0491-5 (Pubitemid 47476932)
19. DT Price RE Coleman RP Liao CN Robertson TJ Polascik TR DeGrado 2002 Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer J Urol 168 1 273 280 12050555 10.1016/S0022-5347(05)64906-3 (Pubitemid 34640843)
20. H Shindou D Hishikawa T Harayama K Yuki T Shimizu 2009 Recent progress on acyl CoA: lysophospholipid acyltransferase research J Lipid Res 50 Suppl S46 S51 18931347 10.1194/jlr.R800035-JLR200
21. CH Warden M Friedkin 1984 Regulation of phosphatidylcholine biosynthesis by mitogenic growth factors Biochim Biophys Acta 792 3 270 280 6365172 1:CAS:528:DyaL2cXhtlegs7w%3D (Pubitemid 14159365)
22. CH Warden M Friedkin 1985 Regulation of choline kinase activity and phosphatidylcholine biosynthesis by mitogenic growth factors in 3T3 fibroblasts J Biol Chem 260 10 6006 6011 2987212 1:CAS:528:DyaL2MXitF2jsbg%3D (Pubitemid 15072502)
23. E Ackerstaff BR Pflug JB Nelson ZM Bhujwalla 2001 Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells Cancer Res 61 9 3599 3603 11325827 1:CAS:528:DC%2BD3MXjsFCgtLY%3D (Pubitemid 32694969)
24. SA Kwee TR DeGrado JN Talbot F Gutman MN Coel 2007 Cancer imaging with fluorine-18-labeled choline derivatives Semin Nucl Med 37 6 420 428 17920349 10.1053/j.semnuclmed.2007.07.003 (Pubitemid 47498259)
25. S Belloli E Jachetti RM Moresco M Picchio M Lecchi S Valtorta, et al. 2009 Characterization of preclinical models of prostate cancer using PET-based molecular imaging Eur J Nucl Med Mol Imaging 36 8 1245 1255 10.1007/s00259-009- 1091-3 19280188 10.1007/s00259-009-1091-3
26. QH Zheng TA Gardner S Raikwar C Kao KL Stone TD Martinez, et al. 2004 [11C]Choline as a PET biomarker for assessment of prostate cancer tumour models Bioorg Med Chem 12 11 2887 2893 10.1016/j.bmc.2004.03.051 15142549 10.1016/j.bmc.2004.03.051 1:CAS:528:DC%2BD2cXktVKqtrk%3D (Pubitemid 38622124)
27. TR DeGrado SW Baldwin S Wang MD Orr RP Liao HS Friedman, et al. 2001 Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers J Nucl Med 42 12 1805 1814 11752077 1:CAS:528:DC%2BD38XktlOktb8%3D (Pubitemid 34016349)
28. S Korenchuk JE Lehr L MClean YG Lee S Whitney R Vessella, et al. 2001 VCaP, a cell-based model system of human prostate cancer In Vivo 15 2 163 168 11317522 1:STN:280:DC%2BD3MrgsVOgsg%3D%3D (Pubitemid 32328191)
29. ME Kaighn KS Narayan Y Ohnuki JF Lechner LW Jones 1979 Establishment and characterization of a human prostatic carcinoma cell line (PC-3) Invest Urol 17 1 16 23 447482 1:STN:280:DyaE1M7ptlKlsg%3D%3D (Pubitemid 9239413)
30. WA Breeman M de Jong E de Blois BF Bernard M Konijnenberg EP Krenning 2005 Radiolabelling DOTA-peptides with 68Ga Eur J Nucl Med Mol Imaging 32 4 478 485 15655678 10.1007/s00259-004-1702-y 1:CAS:528:DC%2BD2MXjtV2hs70%3D (Pubitemid 40591180)
31. C Decristoforo R Knopp E von Guggenberg M Rupprich T Dreger A Hess, et al. 2007 A fully automated synthesis for the preparation of 68Ga-labelled peptides Nucl Med Commun 28 11 870 875 17901771 10.1097/MNM.0b013e3282f1753d 1:CAS:528:DC%2BD2sXhtFSnt7rL (Pubitemid 47494113)
32. R Iwata C Pascali A Bogni S Furumoto K Terasaki K Yanai 2002 [18F]Fluoromethyl triflate, a novel and reactive [18F]fluoromethylating agent: preparation and application to the on-column preparation of [18F]fluorocholine Appl Radiat Isot 57 3 347 352 12201141 10.1016/S0969-8043(02)00123-9 1:CAS:528:DC%2BD38XltlegtLk%3D (Pubitemid 34761932)
33. AK Buck K Herrmann C Shen T Dechow M Schwaiger HJ Wester 2009 Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine Methods 48 2 205 215 19318128 10.1016/j.ymeth.2009.03.009 1:CAS:528:DC%2BD1MXmvFymtbo%3D
34. RT Jensen JF Battey ER Spindel RV Benya 2008 International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states Pharmacol Rev 60 1 1 42 18055507 10.1124/pr.107.07108 1:CAS:528:DC%2BD1cXks1GjsLk%3D (Pubitemid 351439216)
35. R Cescato T Maina B Nock A Nikolopoulou D Charalambidis V Piccand, et al. 2008 Bombesin receptor antagonists may be preferable to agonists for tumour targeting J Nucl Med 49 2 318 326 10.2967/jnumed.107.045054 18199616 10.2967/jnumed.107.045054 1:CAS:528:DC%2BD1cXivVOltb8%3D (Pubitemid 351225672)
36. JC Garrison TL Rold GL Sieckman F Naz SV Sublett SD Figueroa, et al. 2008 Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model Bioconjug Chem 19 9 1803 1812 18712899 10.1021/bc8001375 1:CAS:528: DC%2BD1cXhtVShtLbK
37. T Ebenhan M Honer SM Ametamey PA Schubiger M Becquet S Ferretti, et al. 2009 Comparison of [18F]-tracers in various experimental tumour models by PET imaging and identification of an early response biomarker for the novel microtubule stabilizer patupilone Mol Imaging Biol 11 5 308 321 19462209 10.1007/s11307-009-0216-1 1:STN:280:DC%2BD1Mris1aitQ%3D%3D
38. C Greco GL Cascini O Tamburrini 2008 Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse? Prostate Cancer Prostatic Dis 11 2 121 128 18180806 10.1038/sj.pcan.4501028 1:STN:280:DC%2BD1czgvFWrsw%3D%3D (Pubitemid 351676598)
39. JR Buscombe E Bombardieri 2005 Imaging cancer using single photon techniques Q J Nucl Med Mol Imaging 49 2 121 131 16010250 1:STN:280: DC%2BD2Mzls1Kmtw%3D%3D